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Background: Little is known about the relationship between sarcopenia and mild cognitive 
impairment (MCI) in low- and middle-income countries (LMICs).  
Objective: This study aimed to investigate this association among community-dwelling adults 
aged ≥65 years from six LMICs. 
Methods: Cross-sectional, nationally representative data from the Study on Global Ageing and 
Adult Health (SAGE) were analyzed. These data were obtained in China, Ghana, India, Mexico, 
Russia, and South Africa in 2007-2010. Participants were considered to have sarcopenia if they 
had low skeletal muscle mass (i.e., lower skeletal mass index) and a weak handgrip strength. 
MCI was defined using the National Institute on Aging-Alzheimer’s Association criteria. 
Multivariable logistic regression analysis was conducted to assess associations. 
Results: The final analytical sample consisted of 12912 individuals aged ≥65 years with 
preservation in functional abilities without stroke (mean [standard deviation] age 72.2 [10.8] 
years; 45.2% males). The overall prevalence of sarcopenia and MCI were 11.3% and 18.1%, 
respectively. After adjusting for potential confounders, there was a positive association between 
sarcopenia and MCI in all countries (i.e., odds ratio [OR]>1) with the exception of South Africa, 
and the overall estimate was OR=1.60 (95% confidence interval [CI]=1.32-1.93) with a low 
level of between-country heterogeneity (I2=0.0%).  
Conclusion: There was a positive association between sarcopenia and MCI in this sample of 
older adults living in LMICs. Causality should be assessed in future longitudinal research, while 
the utility of sarcopenia as a marker of MCI should also be investigated. 
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The world is presently facing an unprecedented ageing of the population. Indeed, the proportion 
of adults aged >60 years will increase from 12% in 2015 to 22% in 2050 [1]. The burden related 
to this global ageing is particularly high in low- and middle-income countries (LMICs), with 
four out of five older adults projected to be living in LMICs by 2050. In this context, the number 
of people with dementia is rising [2], with the majority of these individuals residing in LMICs 
[3]. Unfortunately, there are currently no effective treatments for dementia, and thus, it is of 
vital importance to identify the correlates or risk factors of its preclinical stage such as mild 
cognitive impairment (MCI) to prevent dementia or delay its onset. MCI has a high conversion 
rate to dementia (annual conversion rate between 5% and 10%) [4] and is increasingly being 
recognized as an important stage to intervene.  
 
Well-known risk factors for MCI are age, the APOE ε4 allele, low educational level, 
hypertension, and depressive symptoms [5,6]. In the past years, there has also been a growing 
body of literature showing that sarcopenia may be an additional risk factor or marker of 
cognitive decline. Sarcopenia is one of the most prominent physiological changes related with 
aging, and is characterized by a gradual loss of muscle mass and function [7]. Sarcopenia may 
increase the risk for cognitive decline [8], and this relationship may be explained by shared 
pathophysiological mechanisms (e.g., inflammation [9,10], hormonal dysregulations [11,12] 
and malnutrition [13,14]), brain atrophy [15] and several mediating factors (e.g., depression 
[16,17], metabolic syndrome [18,19] and hypertension [20,21]). A systematic review and meta-
analysis of 15 studies showed that sarcopenia was significantly and positively associated with 
cognitive impairment (odds ratio [OR]=2.25, 95% confidence interval [CI]=1.70-2.97) [22]. 
Furthermore, although not specifically on sarcopenia, previous studies have shown that 
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individual components of sarcopenia (e.g., slow gait speed or decreased physical performance) 
increase the risk for future cognitive decline and dementia [23,24]. 
 
However, to the best of our knowledge, apart from two small studies conducted in Japan and 
South Korea [25,26], all previous studies on sarcopenia and cognition were on cognitive 
function in general (which may not necessary carry a high risk for conversion to dementia) and 
not MCI. Furthermore, there is very little information on sarcopenia and/or MCI from LMICs, 
despite the projected sharp increase in these conditions in the coming years due to rapid 
population ageing in this setting. Therefore, the goal of this study was to investigate the 
association between sarcopenia and MCI in community-dwelling adults aged ≥65 years from 
six LMICs (China, Ghana, India, Mexico, Russia, and South Africa), which broadly represent 
different geographical locations and levels of socio-economic and demographic transition.  
 
Materials and Methods 
 
The survey 
Data from the Study on Global Ageing and Adult Health (SAGE) were used for the present 
study. All data can be found at http://www.who.int/healthinfo/sage/en/. Initially, the SAGE 
survey aimed to collect data on health and well-being in LMICs [27]. There were six countries 
(China, Ghana, India, Mexico, Russia, and South Africa) included in the SAGE survey between 
2007 and 2010. All countries were LMICs at the time of the acquisition of the data (low-income 
country: Ghana; lower middle-income countries: China and India; and upper middle-income 
countries: Mexico, Russia and South Africa). The methodology of the SAGE survey has been 
described in detail elsewhere [28]. Briefly, the samples were obtained with a multistage 
clustered sampling method, and were nationally representative. In each participating country, 
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the SAGE survey targeted 6000 households, and all household members had a nonzero 
probability of being selected [29]. Participants of the survey were aged ≥18 years, and those 
aged ≥50 years were oversampled. Data were obtained during face-to-face interviews 
conducted by trained staff using a standard questionnaire. This questionnaire was translated 
using standard procedures, and this allowed comparability between countries. China (93%) and 
Mexico (53%) had the highest and the lowest response rate, respectively. The structure of the 
populations was further taken into account and, based on statistics provided by the United 
Nations Statistical Division, sampling weights were constructed. Finally, formal ethical 
approval was obtained from the WHO Ethical Review Committee and local ethics research 
review boards, while written informed consent was obtained for each individual participant.  
 
Study sample 
The flow chart of participants is provided in Figure 1. The final analytical sample consisted of 
12912 individuals aged ≥65 years with preservation in functional abilities and without stroke.  
 
Sarcopenia (exposure) 
Following the criteria of the revised European consensus on the definition and diagnosis of 
sarcopenia [30], participants were considered to have sarcopenia if they had low skeletal muscle 
mass (SMM) (i.e., lower skeletal mass index [SMI]) and weak handgrip strength, while 
participants were considered to have severe sarcopenia if they had low SMM, weak handgrip 
strength, and low gait speed. SMM was calculated based on the equation proposed by Lee and 
colleagues: SMM= 0.244*weight + 7.8*height + 6.6*sex – 0.098*age + race – 3.3 (where 
female=0 and male=1; race=0 [White and Hispanic],  race=1.9 [Black] and race=-1.6 [Asian]) 
[31]. SMM was further divided by BMI based on measured weight and height to create a SMI 
[32]. Low SMM corresponded to the lowest quintile of sex-stratified values of SMI. Gait speed 
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was based on a 4m timed walk and was measured by asking the participant to walk at a normal 
pace. The time to completion of the 4m walk was recorded by the interviewer. Slow gait speed 
corresponded to the lowest quintile of height, age, and sex-stratified values of walking speed 
[33]. Weak handgrip strength was defined as <27kg for men and <16kg for women using the 
average value of the two handgrip measurements of the dominant hand [30].  
 
Mild cognitive impairment (outcome) 
MCI was defined following the recommendations of the National Institute on Aging-
Alzheimer’s Association [34]. Algorithms already used in previous SAGE studies were applied 
to identify people with MCI [35]. Participants were considered to have MCI if at least one of 
the four following criteria was fulfilled:  
(a) Concern about a change in cognition: individuals were considered to have concern about a 
change in cognition if they answered “bad” or “very bad” to the question “How would you best 
describe your memory at present?” or “worse” to the question “Compared to 12 months ago, 
would you say your memory is now better, the same or worse than it was then?”. 
(b) Objective evidence of impairment in one or more cognitive domains: several aspects of 
cognition were assessed. Learning and episodic memory was tested using the word list 
immediate and delayed verbal recall from the Consortium to Establish a Registry for 
Alzheimer’s disease [36]; attention and working memory were tested using the digit span 
forward and backwards from the Weschler Adult Intelligence Scale [37]; and verbal fluency 
was tested using the animal naming task [36]. 
(c) Preservation of independence in functional abilities: questions on self-reported difficulties 
in activities of daily living (ADL) in the past month were used to assess preservation of 
independence in functional abilities [38]. These questions were: “How much difficulty did you 
have in getting dressed?” and “How much difficulty did you have with eating (including cutting 
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up your food)?” (answer options: “none”, “mild”, “moderate”, “severe”, and “extreme (cannot 
do)”). Preservation of independence in functional activities corresponded to answering “none”, 
“mild” or “moderate” to both questions. Participants without preservation of independence in 
functional activities were excluded from the analyses (i.e., 962 individuals aged ≥65 years). 
 (d) No dementia: if adults were unable to undertake the survey because of cognitive 
impairments, these individuals were not included in the study. 
 
Control variables 
Past literature was used to select the control variables to include in the statistical analyses [39]. 
These variables were years of education, wealth quintiles based on income, physical activity, 
smoking (never, past, current), alcohol use in the past 30 days (yes or no), diabetes, and 
hypertension. Diabetes was based solely on lifetime self-reported diagnosis. Hypertension was 
defined using one of the following three criteria: systolic blood pressure ≥140 mmHg; diastolic 
blood pressure ≥90 mmHg; or self-reported diagnosis. Physical activity was assessed with the 
Global Physical Activity Questionnaire and, using conventional cut-offs [40], physical activity 
was included in the analyses as a three-category variable (low, moderate and high). 
 
 Statistical analysis 
The statistical analysis was performed with Stata 14.1 (Stata Corp LP, College station, Texas). 
Given that sarcopenia and MCI are age-related conditions, only participants aged ≥65 years 
were included in the analyses. Individuals with stroke were also excluded as this condition can 
lead to both cognitive decline and sarcopenia [41,42]. A country-wise multivariable logistic 
regression analysis was conducted to assess the association between sarcopenia or severe 
sarcopenia (exposures) and MCI (outcome). The regression analysis was adjusted for years of 
education, wealth, physical activity, smoking, alcohol use, diabetes, and hypertension. 
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Furthermore, in order to assess the between-country heterogeneity that may exist in the 
association between sarcopenia and MCI, the Higgins’s I2 was calculated based on estimates 
from each country. The Higgins’s I2 corresponds to the degree of heterogeneity that is not 
explained by sampling error with a value of <40% often considered as negligible and 40-60% 
as moderate heterogeneity [43]. A pooled estimate was obtained by fixed-effect meta-analysis. 
Sex-stratified analyses were also conducted. All variables were included in the models as 
categorical variables with the exception of years of education (continuous variable). Complete 
case analysis was done. The sample weighting and the complex study design were taken into 
account in the analyses. Results from the regression analyses are presented as ORs with 95% 




The mean (standard deviation) age of the sample was 72.2 (10.8) years and 45.2% were males 
(Table 1). Percent of missing values for the variables used in the study are displayed in Table 
S1, while differences in sample characteristics between those missing and not missing values 
on either sarcopenia or mild cognitive impairment are shown in Table S2. The overall 
prevalence of MCI was 18.1%, while that of sarcopenia and severe sarcopenia were 11.3% and 
2.5%, respectively. In the overall sample, compared to those without sarcopenia, the prevalence 
of MCI was much higher in people with sarcopenia (27.6% vs. 16.8%) (Figure 2) and severe 
sarcopenia (25.5% vs. 17.6%) (Appendix Figure S1). Figure 3 illustrates the country-wise 
association between sarcopenia and MCI based on multivariable logistic regression, and the 
overall estimate based on meta-analysis in the sample including both males and females. There 
was a positive association between sarcopenia and MCI in all countries (i.e., OR>1) with the 
exception of South Africa, and the overall estimate was OR=1.60 (95%CI=1.32-1.93) with a 
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low level of between-country heterogeneity (I2=0.0%). Overall, significant positive 
associations were also observed in samples restricted to males (OR=1.74; 95%CI=1.35-2.23) 
and females (OR=1.63; 95%CI=1.25-2.13) (Figure 4). In terms of severe sarcopenia, the 
pooled OR (95%CI) was 1.78 (1.21-2.63) in the overall sample (Appendix Figure S2), while 
that for males and females was 1.79 (1.05-3.07) and 1.74 (1.06-2.85), respectively (Appendix 





In this multinational study including nearly 13000 older adults living in LMICs, sarcopenia and 
severe sarcopenia were associated with a significant 1.60- and 1.78-fold increase in the risk of 
MCI, respectively. These results were corroborated in the sex-stratified analyses. To the best of 
our knowledge, this is the first multinational study to investigate the relationship between 
sarcopenia and MCI, and the first from LMICs, while it is also the largest study on this topic to 
date. 
 
Interpretation of findings  
The findings of our study are in line with the only two studies on this topic (i.e., sarcopenia and 
MCI) from Japan and South Korea. In the Japanese study which included 250 older individuals, 
of which approximately 20% had sarcopenia and 40% MCI, there was a positive and significant 
association between sarcopenia and MCI (OR=2.96) after adjustment for several factors such 
as smoking status and cardiovascular diseases [25]. These findings were corroborated in the 
other study conducted among 201 community-dwelling women living in South Korea, where 
sarcopenia was associated with a 4.50-fold increase in the odds of MCI [26]. In addition, several 
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studies have also found that sarcopenia is a risk factor for an overall poor cognitive 
performance. For example, a systematic review and meta-analysis including 5994 individuals 
reported a significant and positive association between sarcopenia and cognitive impairment 
(OR=2.25) [44]. The higher OR in the Japanese and Korean studies than ours may be explained 
by the fact that these previous studies did not control for several potentially important 
confounders (e.g., wealth and physical activity), while it can also be attributable to 
methodological differences. In our study which used standardized methods across countries, 
there was no significant between-country heterogeneity in the association between sarcopenia 
and MCI in the overall sample, suggesting that this relationship may not be context-specific at 
least in LMICs.  
 
Although the mechanisms linking sarcopenia and MCI are unclear, two hypotheses may explain 
this relationship. First, chronic physical and psychiatric conditions may be involved as 
mediating factors in the sarcopenia-MCI relationship. One chronic condition likely playing a 
major role in this association is metabolic syndrome. A systematic review and meta-analysis of 
12 studies including middle-aged and older adults without obesity showed a positive association 
between sarcopenia and metabolic syndrome, and this may involve insulin resistance and 
decreased secretion of myokines protecting against the deleterious effects of the adipose tissue 
[19]. As a matter of fact, the muscle plays a key role in the metabolism of glucose and in the 
prevention of insulin resistance [45]. Meanwhile, a study including 2102 community elders 
from China found that those with metabolic syndrome were at an increased risk for MCI 
compared with their counterparts without metabolic syndrome [18], and potential underlying 
mechanisms are cerebrovascular disease and an alteration in the β-amyloid deposition [46]. 
Interestingly, depression could also be a major mediating factor in the association between 
sarcopenia and MCI. Indeed, a longitudinal study of 691 older adults living in China revealed 
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that sarcopenia was associated with a 3.57-fold increase in the 12-month incidence of 
depressive symptoms [17]. Another prospective study using data of 8855 patients from the 
United States indicated that late-life depression was a risk factor for progression from normal 
cognition to MCI, and it was hypothesized that sleep disruption and changes in the activity of 
frontal and limbic circuits might contribute to the depression-MCI relationship [16]. Besides 
chronic physical and psychiatric conditions, the association between sarcopenia and MCI may 
be explained by brain atrophy. It was observed in a study of 70 patients with early Alzheimer’s 
disease and 70 patients without dementia that lean mass was reduced in the dementia group 
compared with the no dementia group, while lean mass was associated with whole-brain 
volume, white matter volume and global cognitive performance [15]. 
 
Second, it is also possible that sarcopenia and MCI are not causally linked but that they share 
common risk factors such as physiopathological mechanisms including inflammation, 
hormonal dysregulations and malnutrition. In terms of inflammation, a five-year prospective 
cohort study including 115 older adults found that interleukin 6 (IL-6) and C-reactive protein 
(CRP) were risk factors for increased loss of total appendicular skeletal muscle [9]. In addition, 
a longitudinal study, using data from 2574 individuals residing in the United States, indicated 
that systemic inflammation predicted a significant decrease in cognitive performance [10], and 
these deleterious effects may be related to the occurrence of cerebral small vessel disease [47]. 
Next, as for hormonal dysregulation, a study including 337 volunteers aged 64 years and over 
showed that bioavailable testosterone was positively associated with appendicular skeletal 
muscle mass, highlighting the key role played by this anabolic hormone in skeletal muscle 
metabolism [11]. On the other hand, higher levels of serum free testosterone were identified as 
a protective factor against longitudinal decline in visual memory in a US longitudinal study of 
407 elderly men [12]. Finally, malnutrition is a risk factor for both sarcopenia [14] and cognitive 
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impairment [13]. The malnutrition-sarcopenia relationship may be explained by the fact that 
several nutritional factors (e.g., proteins, calcium and vitamin D) are necessary to maintain 
muscle mass [14], while a wide range of different nutrients such as omega-3 fatty acids and 
vitamin E may have a beneficial impact on cognition [48]. 
 
Clinical implications and directions for future research 
Based on these findings, sarcopenia may be a risk factor for the development of MCI, or it may 
serve as a marker of those who are at heightened risk for dementia. If confirmed to be a risk 
factor based on future longitudinal research, it may be important to improve the diagnosis and 
the management of sarcopenia in older adults for the prevention of MCI and ultimately 
dementia. There is presently no pharmaceutical treatment for sarcopenia, making physical 
therapy a key component of the management of this condition. Given that access to 
physiotherapy may be limited in LMICs [49], general practitioners and other health 
professionals should promote an increase in levels of physical activity (resistance and strength 
exercises) in patients diagnosed with or at risk for sarcopenia. As increasing physical activity 
in older adults may also directly reduce the risk of dementia [50], promotion of physical activity 
may have a dual positive effect of addressing or preventing both sarcopenia and dementia in 
LMICs. Although there is also some evidence suggesting that dietary interventions may 
improve muscle outcomes in the elderly population [51], such interventions may be difficult to 
implement in LMICs, where undernutrition and malnutrition are highly common, because the 
cost of these interventions is substantial [52]. In terms of future research, longitudinal data is 
necessary to elucidate direction of associations and causality. Furthermore, more data are 
needed to better comprehend the mechanisms underlying the association between sarcopenia 
and MCI. Finally, a wide range of different criteria are used to define sarcopenia [53], and 
further studies are warranted to harmonize the definition of sarcopenia across the world.  
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Strengths and limitations  
The use of large nationally representative datasets from six LMICs which collectively comprise 
a substantial proportion of the worldwide population [28] is a clear strength of this study. 
Nonetheless, the study results must be interpreted in light of several limitations. First, SMM 
was estimated using an equation and was not directly assessed due to lack of data on objective 
measures. However, previous research has reported good concordance rates between this 
formula and gold standard methods (e.g., dual-energy X-ray absorptiometry and magnetic 
resonance imaging) [39]. Second, the equation used to estimate SMM was validated in a US 
population [31], and the estimation of SMM with this equation may not be accurate in other 
populations. Third, as the study design did not allow for formal dementia diagnoses, it is 
possible that some people with mild dementia were included in the analyses. That being said, 
the prevalence of MCI in our sample was similar to figures previously reported in the literature 
[54]. Fourth, diet was not included as a control variable in the analyses, although it may be 
associated with both sarcopenia and MCI [55,56]. Thus, residual confounding due to this factor 
is possible. Fifth, there is currently no consensus regarding the definition of MCI [57] and the 
acceptable level of functional impairment that individuals with MCI could present. We used a 
definition based on disabilities in eating and getting dressed so as not to exclude individuals 
with MCI but with disability not related with their cognitive ability. However, it is possible for 
the results to have differed if a different definition for preservation on functional abilities was 
used. Finally, since this was a cross-sectional study, causality and temporality of the sarcopenia-




Overall, sarcopenia was associated with higher odds for MCI in this sample of approximatively 
13000 adults aged ≥65 years from LMICs. Future studies should investigate the mechanisms 
underlying the sarcopenia-MCI association, while the utility of sarcopenia as a marker of MCI 
should also be assessed. In addition, longitudinal studies are necessary to elucidate whether 
addressing sarcopenia may lead to reduction in MCI and ultimately dementia. Finally, 
addressing modifiable risk factors (e.g., nutrition and physical activity) for both conditions may 
help reduce this comorbidity.  
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Table 1 Sample characteristics 















Mild cognitive impairment Yes 18.1 25.9 9.3 12.3 17.1 14.5 11.0 
Sarcopenia Yes 11.3 11.7 8.6 13.0 9.8 8.1 6.2 
Severe sarcopenia Yes 2.5 1.6 4.0 2.5 2.9 4.9 3.3 
Sex Male 45.2 46.3 52.3 52.8 45.6 31.7 37.6 
Age Mean (SD) 72.2 (10.8) 72.1 (10.5) 73.9 (13.8) 71.2 (9.3) 73.9 (14.2) 73.7 (9.7) 72.8 (14.8) 
Years of education Mean (SD) 5.2 (9.3) 4.6 (9.1) 2.7 (8.7) 3.2 (7.1) 4.1 (9.1) 9.8 (6.1) 5.4 (10.7) 
Physical activity High  37.0 32.8 55.1 38.0 27.2 44.2 19.7 
 Moderate 26.0 30.8 12.6 26.8 25.9 18.6 14.9 
 Low 37.0 36.5 32.3 35.2 46.9 37.2 65.5 
Smoking Never 62.3 67.9 73.7 42.5 58.9 80.6 67.8 
 Quit 29.8 23.6 11.8 51.8 17.4 9.9 20.1 
 Current 8.0 8.5 14.4 5.6 23.7 9.4 12.1 
Alcohol use Yes 14.5 17.7 27.2 5.6 12.3 21.8 11.0 
Diabetes Yes 8.2 9.1 3.2 6.8 16.4 8.5 11.1 
Hypertension Yes 62.2 68.6 58.9 40.8 73.6 80.8 82.3 
Abbreviation: SD Standard deviation. 








Figure 2 Prevalence of mild cognitive impairment by presence or absence of sarcopenia 





























Figure 3 Association between sarcopenia (exposure) and mild cognitive impairment (outcome) 
estimated by multivariable logistic regression 
Abbreviation: OR Odds ratio; CI Confidence interval.  
Models are adjusted for years of education, wealth, physical activity, smoking, alcohol use, diabetes, and 
hypertension. 








Figure 4 Association between sarcopenia (exposure) and mild cognitive impairment (outcome) 
among (A) males and (B) females estimated by multivariable logistic regression 
Abbreviation: OR Odds ratio; CI Confidence interval.  
Models are adjusted for years of education, wealth, physical activity, smoking, alcohol use, diabetes, and 
hypertension. 






Figure S1 Prevalence of mild cognitive impairment by presence or absence of severe 
sarcopenia 
Bars denote 95% confidence interval. 






















Prevalence of mild cognitive impairment (%)
No severe sarcopenia Severe sarcopenia
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Figure S2 Association between severe sarcopenia (exposure) and mild cognitive impairment 
(outcome) estimated by multivariable logistic regression 
Abbreviation: OR Odds ratio; CI Confidence interval.  
Models are adjusted for years of education, wealth, physical activity, smoking, alcohol use, diabetes, and 
hypertension. 
Overall estimate was obtained by meta-analysis with fixed effects. 







Figure S3 Association between severe sarcopenia (exposure) and mild cognitive impairment 
(outcome) among (A) males and (B) females estimated by multivariable logistic regression 
Abbreviation: OR Odds ratio; CI Confidence interval.  
Models are adjusted for years of education, wealth, physical activity, smoking, alcohol use, diabetes, and 
hypertension. 
Overall estimate was obtained by meta-analysis with fixed effects. 
Estimates for South Africa could not be obtained due to the very small number of people with severe sarcopenia. 
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Table S1 Percent of missing values for the variables used in the study 
Variable % missing 




Years of education 1.29 
Wealth 0.38 
Physical activity 0.01 
Smoking 0.28 






Table S2 Difference in sample characteristics between those missing and not missing values 
on either sarcopenia or mild cognitive impairment 
    
Missing values on 
sarcopenia or mild 
cognitive impairment 
  
Characteristic  Category No Yes P-valuea 
Sex Male 46.3 38.4 0.005 
Age Mean (SD) 71.9 (10.5) 74.0 (12.0) <0.001 
Years of education Mean (SD) 4.9 (9.2) 7.1 (9.4) <0.001 
Wealth Poorest 21.8 19.2 0.241 
 Poorer 20.3 25.5  
 Middle 20.1 22.7  
 Richer 18.2 12.9  
 Richest 19.7 19.7  
Physical activity High  38.5 28.1 <0.001 
 Moderate 26.9 20.9  
 Low 34.7 51.0  
Smoking Never 60.5 72.7 <0.001 
 Quit 31.8 17.9  
 Current 7.7 9.4  
Alcohol use Yes 14.6 13.6 0.563 
Diabetes Yes 7.9 9.7 0.238 
Hypertension Yes 61.5 66.6 0.143 
a P-value was calculated based on Chi-squared tests and Student’s t-tests for categorical and continuous 
variables, respectively.  
 
